ClinicalTrials.gg

Program

zuberitamab

Also written as “Zuberitamab 1000mg”, “HS006+CHOP” and “Zuberitamab 600mg”.

Its studies are mostly in Glomerulonephritis, Membranous · Lymphoma, Large B-Cell, Diffuse, led by 2 companies.

Furthest: phase 3, since Sep 15, 20263 company-led studies, 2 open or runningNext primary completion: Mar 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioRay Pharmaceutical22 open or runningphase 3since Sep 15, 2026Oct 13, 2024Mar 31, 2027phase 2 · NCT06642909
Zhejiang Hisun Pharmaceutical10 open or runningphase 2since Mar 26, 2018Mar 26, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 26, 2018First study: phase 2 study in Lymphoma, Large B-Cell, DiffuseNew to Zhejiang Hisun PharmaceuticalZhejiang Hisun Pharmaceutical · NCT03485118 · 137 enrolled
  2. Oct 13, 2024BioRay Pharmaceutical's first study: phase 2 study in Primary Membranous NephropathyNew to BioRay PharmaceuticalBioRay Pharmaceutical · NCT06642909 · 135 enrolled · China
  3. Sep 15, 2026Phase 3 study in Primary Membranous NephropathyPhase 3 reachedBioRay Pharmaceutical · NCT07830433 · 150 planned · China

Ahead

  1. Mar 31, 2027Primary completion: phase 2 study in Primary Membranous NephropathyBioRay Pharmaceutical · NCT06642909
  2. Dec 2029Primary completion: phase 3 study in Primary Membranous NephropathyBioRay Pharmaceutical · NCT07830433

TargetBeta

MS4A1 →read by rule
“A recombinant human-mouse chimeric monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, ”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule

Other programs on MS4A1

ProgramCompanyFurthest phaseStudies
RituximabruleHoffmann-La Rochephase 4175
ocrelizumabruleHoffmann-La Rochephase 442
obinutuzumabruleHoffmann-La Rochephase 442
ublituximabruleTG Therapeuticsphase 323
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
Anti-CD20 Monoclonal Antibody MIL62rulebeijing-mabworks-biotech-co-ltdphase 310
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07830433Primary Membranous Nephropathy · China3Not yet recruitingBioRay PharmaceuticalDec 2029150
NCT06642909Primary Membranous Nephropathy · China2Active, not recruitingBioRay PharmaceuticalMar 31, 2027135
NCT03485118Lymphoma, Large B-Cell, Diffuse2CompletedZhejiang Hisun PharmaceuticalAug 12, 2016137

How it is read

Names in the registry

  • “Zuberitamab 1000mg”, 2 entries
  • “HS006+CHOP”, 2 entries
  • “Zuberitamab 600mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.